Ann: AACC conference summary and CEO interview, page-39

You are correct, hippies, they absolutely were working shareholders of Cellestis and I personally spoke with Rachel who confirmed she was. From memory Charlie and (maybe-my memory's not perfect) Shaun was too. I held also at the time, in fact I introduced the topic and she then volunteered the info. They were devastated at the takeover by Qiagen and when they walked out on the last day, they more or less vowed to do their utmost to make the next company they collaborated at, stay Australian or at least fully realise its true potential. Guess where they moved to??

This is what will never appear in a balance sheet under intangible assets - the drive and commitment of the most important asset of any coy, its people. It's been completely un-rated by investors outside HC & other believers and that's made ADO an easy target for the naysayers, in spite of its unique tech.

I mean, just look at the title of Josh's presentation: “Solving an Intractable Problem - Mitigating Sample Specific Interferences in Clinical Samples Utilizing a Novel Surface Chemistry Approach”*.

I would love a photo, I would imagine it will be standing room only.

I think the potential of ADO is so massive that it's going to be unrealistic to hope that it stays Aust, it would be fantastic, but commercial reality will mean an offer sooner or later, most likely. I am really regretting not being able to get to the site visit this time, to personally congratulate the team. There is not one person in the place not fully committed, focused, and sooooooo smart (at least by my standards).

Yes it's been a long road, but the beginning of real, broad-based recognition is about to dawn, with the inevitable rewards that will bring.

Call me over enthusiastic, maybe I am. But let's see how the scientific community judge this rough diamond tomorrow. The first facet is peeking through.

Congratulations to the Anteo team.